RT Journal
A1 Tan J, Pileggi A, Ricordi C
T1 STem cell therapy in kidney transplantation—reply
JF JAMA
JO JAMA
YR 2012
FD July 11
VO 308
IS 2
SP 130
OP 131
DO 10.1001/jama.2012.6372
UL http://dx.doi.org/10.1001/jama.2012.6372
AB 
In Reply: Human MSCs obtained from marrow mononuclear cells were cultured in low-glucose Dulbecco-modified Eagle medium (Gibco-Invitrogen) supplemented with 10% human platelet lysates (Beijing Sino-US Fuxing). Confluent MSCs were detached with 0.05% Trypsin-EDTA (Gibco-Invitrogen).1 Safety measures proposed by the Food and Drug Administration in 2008 for Human Somatic Cell Therapy Investigational New Drug Applications were followed. As discussed, putative MSC identity markers2 were confirmed by flow cytometry prior to each inoculum; also, passage-4 MSCs differentiated in vitro into bona fide mesenchymal tissues (bone, cartilage, fat or muscle).2